glp-1 cons 2026 Employee Benefits Trends: Should You Cover GLP‑1s for Weight Loss? Is Ozempic Actually The Best

Most likely

A stronger injection Lilly is getting closer to finishing its clinical trials on what could be the most powerful GLP-1 drug yet, called retatrutide

The idea that in the age of Ozempic, "hotness" is a requirement for finding a job is something my colleague Amanda Hoover wrote about recently, and pointed to an unsettling data point: "The Society for Human Resource Management surveyed about 1,000 human resource professionals in 2023 and found that about a quarter said obese employees are more likely to be perceived as unmotivated and lazy than slimmer workers." The positive effects on men's jobs from starting GLP-1s were much smaller, and the data on unpartnered men were too small to analyze

No estimation needed

The discontinuation rates due to adverse events, which were comparable to placebo, suggest that the transition to oral orforglipron is generally well-tolerated by patients already acclimated to incretin therapy

*Based on self-reported member data on a Found program from members with no prior weight loss medication use, who reported weight loss of 12.1% in 6 months on compounded tirzepatide, as of April 2026